. . . "Bioavailability after IM administration is 63%."@en . . "withdrawn"@en . "Humans and other mammals"@en . "Alefacept"@en . . . " "@en . "As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis"@en . . . "# Koo JY, Bagel J, Sweetser MT, Ticho BS: Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study. J Drugs Dermatol. 2006 Jul-Aug;5(7):623-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16865867 # Krell JM: Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept. J Am Acad Dermatol. 2006 Jun;54(6):1099-101. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16713481 # Parrish CA, Sobera JO, Robbins CM, Cantrell WC, Desmond RA, Elewski BE: Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol. 2006 Apr;5(4):339-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16673801 # American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995. Alefacept; [updated 2014 Jan 30; cited 2014 Nov 11]. Available from http://web.b.ebscohost.com.login.ezproxy.library.ualberta.ca/dynamed/detail?vid=9&sid=78010ea4-6f9c-4d5a-a7df-a148b3891321%40sessionmgr110&hid=123&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=232900"@en . . . . . . . "Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen."@en . . "ASP0485"@en . "~270 hours"@en . "approved"@en . "222535-22-0"@en . "Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD."@en . "While it has been found to cross the placenta in monkeys, it is not yet known if it also diffuses into breast milk. "@en . . . . .